

ALEXION PHARMACEUTICALS INC

Form 4

November 29, 2007

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
DUBIN THOMAS I H

(Last) (First) (Middle)

C/O ALEXION
PHARMACEUTICALS INC, 352
KNOTTER DRIVE

(Street)

CHESHIRE, CT 06410

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading
Symbol

ALEXION PHARMACEUTICALS
INC [ALXN]

3. Date of Earliest Transaction
(Month/Day/Year)
11/28/2007

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director _____ 10% Owner
____X____ Officer (give title _____ Other (specify
below) below)
SVP & General Counsel

6. Individual or Joint/Group Filing(Check
Applicable Line)
____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock, par value \$.0001 per share	11/28/2007		M	300 ⁽¹⁾ D	\$ 74.26 21,197	D	
Common Stock, par value \$.0001 per share	11/28/2007		M	100 D	\$ 74.27 21,097	D	

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Common Stock, par value \$.0001 per share	11/28/2007	M	100	D	\$ 74.28	20,997	D
Common Stock, par value \$.0001 per share	11/28/2007	M	100	D	\$ 74.29	20,897	D
Common Stock, par value \$.0001 per share	11/28/2007	M	100	D	\$ 74.3	20,797	D
Common Stock, par value \$.0001 per share	11/28/2007	M	500	D	\$ 74.32	20,297	D
Common Stock, par value \$.0001 per share	11/28/2007	M	100	D	\$ 74.35	20,197	D
Common Stock, par value \$.0001 per share	11/28/2007	M	800	D	\$ 74.37	19,397	D
Common Stock, par value \$.0001 per share	11/28/2007	M	200	D	\$ 74.38	19,197	D
Common Stock, par value \$.0001 per share	11/28/2007	M	300	D	\$ 74.39	18,897	D
Common Stock, par value \$.0001 per share	11/28/2007	M	100	D	\$ 74.4	18,797	D
	11/28/2007	M	400	D		18,397	D

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Common Stock, par value \$.0001 per share					\$ 74.41		
Common Stock, par value \$.0001 per share	11/28/2007	M	100	D	\$ 74.42	18,297	D
Common Stock, par value \$.0001 per share	11/28/2007	M	100	D	\$ 74.43	18,197	D
Common Stock, par value \$.0001 per share	11/28/2007	M	662	D	\$ 74.44	17,535	D
Common Stock, par value \$.0001 per share	11/28/2007	M	900	D	\$ 74.46	16,635	D
Common Stock, par value \$.0001 per share	11/28/2007	M	300	D	\$ 74.47	16,335	D
Common Stock, par value \$.0001 per share	11/28/2007	M	400	D	\$ 74.52	15,935	D
Common Stock, par value \$.0001 per share	11/28/2007	M	400	D	\$ 74.54	15,535	D
Common Stock, par value \$.0001 per share	11/28/2007	M	200	D	\$ 74.57	15,335	D
	11/28/2007	M	100	D		15,235	D

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 4

Common
Stock, par
value
\$.0001 per
share

\$
74.58

Common
Stock, par
value
\$.0001 per
share

11/28/2007

M

500

D

\$
74.59

14,735

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repor Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

DUBIN THOMAS I H
C/O ALEXION PHARMACEUTICALS INC
352 KNOTTER DRIVE
CHESHIRE, CT 06410

SVP & General Counsel

Signatures

/s/ Thomas
Dubin

11/29/2007

Date

Reporting Owners

Signature of
Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Multiple forms filed by Thomas Dubin with respect to transactions that occurred on November 28, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.